Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4315989 | 0.98 | DYRK1A (0.50) | DYRK1AL3MBTL1KDM4EMAPTRAB9A | |
| SCHEMBL9611694 | 0.74 | DYRK1A (0.52) | DYRK1AL3MBTL1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL18306988 | 0.74 | DYRK1A (0.52) | DYRK1AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL24087053 | 0.74 | DYRK1A (0.52) | DYRK1AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19053825 | 0.74 | DYRK1A (0.52) | DYRK1AKDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24997465 | 0.71 | DYRK1A (0.49) | DYRK1AKDM4EMAPTRAB9AALDH1A1 | |
| SCHEMBL25124496 | 0.69 | DYRK1A (0.51) | DYRK1AKDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12850678 | 0.69 | DYRK1A (0.47) | DYRK1AL3MBTL1NAMPT | |
| SCHEMBL23773807 | 0.69 | DYRK1A (0.47) | DYRK1AL3MBTL1ALDH1A1HPGDNPC1 | |
| SCHEMBL12961000 | 0.69 | DYRK1A (0.47) | DYRK1AKDM4EMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| CN-112409385-B | Azaaryl compounds and uses thereof | 上海青煜医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1699762-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | DYRK1A 3719/4885L3MBTL1 4141/4885KDM4E 2283/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | DYRK1A 967/4885L3MBTL1 4084/4885KDM4E 2742/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | DYRK1A 3517/4885L3MBTL1 2293/4885KDM4E 503/4885 |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | DYRK1A 3188/4885L3MBTL1 2620/4885KDM4E 1025/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | DYRK1A 967/4885L3MBTL1 4084/4885KDM4E 2742/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DYRK1A 1569/4885L3MBTL1 399/4885KDM4E 175/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | DYRK1A 1279/4885L3MBTL1 3579/4885KDM4E 1621/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | DYRK1A 4368/4885L3MBTL1 3264/4885KDM4E 2793/4885 |
| US-20090156617-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | DYRK1A 248/4885L3MBTL1 1193/4885KDM4E 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.